Opko Health, Inc. (OPK) Q1 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Opko Health, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:04.455 reduce our remaining convertible debt, and through our recently expanded share repurchase 00:00:04.455 -- 00:00:08.399 authorization, we plan to continue to reduce the number of shares outstanding in the 00:00:08.399 -- 00:00:11.162 most capital efficient way possible. 00:00:11.162 -- 00:00:16.507 Under our share repurchase authorization, we have approximately $159 million remaining, 00:00:16.507 -- 00:00:21.592 which at yesterday's closing price represents more than 113 million shares, 00:00:21.592 -- 00:00:26.322 or more than 14% of our currently outstanding shares. 00:00:26.322 -- 00:00:30.648 As Elias mentioned, we anticipate closing our second transaction with LabPorp later this 00:00:30.648 -- 00:00:33.452 year and will receive $192.5 00:00:33.452 -- 00:00:39.220 million of closing and up to $225 million in total. 00:00:39.220 -- 00:00:43.586 As we look ahead, the following assumptions influence our financial guidance. 00:00:43.586 -- 00:00:48.333 For our pharmaceutical segment, we expect Pfizer to continue to grow sales of Ingenla 00:00:48.333 -- 00:00:51.382 and the overall HGH franchise. 00:00:51.382 -- 00:00:55.788 We assume a stable foreign currency exchange rate for our ex-U.S. 00:00:55.788 -- 00:01:00.795 pharmaceutical businesses, which has recently been challenged with large 00:01:00.795 -- 00:01:03.859 swings in certain territories. 00:01:03.859 -- 00:01:08.085 Our teams have been diligently navigating those challenges through disciplined expense 00:01:08.085 -- 00:01:11.670 control and expect that going forward. 00:01:11.670 -- 00:01:16.877 R&D expenses will reflect higher activities related to our MODX programs, including 00:01:16.877 -- 00:01:22.258 CMC efforts related to our first oncology trial, as well as furt...